Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388656 | 0.90 | HSD11B1 (0.45) | DRD3DRD2DRD4SLC6A5GRIN2B | |
| SCHEMBL5143973 | 0.86 | DRD2 (0.46) | DRD3DRD2DRD4GRIN2BHTR1A | |
| Formic Acid SCHEMBL27903276 | 0.79 | L3MBTL1 (0.47) | OPRM1OPRK1OPRD1PKML3MBTL1 | |
| SCHEMBL5142107 | 0.78 | HSD11B1 (0.43) | DRD3DRD2DRD4L3MBTL1 | |
| SCHEMBL5143825 | 0.78 | HSD11B1 (0.43) | DRD3DRD2DRD4L3MBTL1 | |
| SCHEMBL5145400 | 0.75 | HSD11B1 (0.44) | — | |
| SCHEMBL19260910 | 0.74 | OPRM1 (0.45) | OPRM1PKML3MBTL1 | |
| SCHEMBL5146612 | 0.74 | HSD11B1 (0.42) | DRD2 | |
| SCHEMBL1798916 | 0.74 | L3MBTL1 (0.42) | OPRM1OPRK1OPRD1PKML3MBTL1 | |
| SCHEMBL5144159 | 0.73 | HSD11B1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | DRD3 384/4885DRD2 366/4885DRD4 916/4885 |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | DRD3 180/4885DRD2 217/4885DRD4 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.